Vir Biotechnology President and CEO George Scangos joins Emily Chang following the news that its Covid-19 antibody treatment, co-developed with Glaxo, looks to be effective against the new omicron variant in early testing.
Vir CEO: Omicron Is Probably Not the Last Variant
Tweet on Twitter
Share on Facebook
Pinterest
